1. Home
  2. EMBC vs SYRE Comparison

EMBC vs SYRE Comparison

Compare EMBC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMBC
  • SYRE
  • Stock Information
  • Founded
  • EMBC 1924
  • SYRE 2013
  • Country
  • EMBC United States
  • SYRE United States
  • Employees
  • EMBC N/A
  • SYRE N/A
  • Industry
  • EMBC Medical/Dental Instruments
  • SYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMBC Health Care
  • SYRE Health Care
  • Exchange
  • EMBC Nasdaq
  • SYRE Nasdaq
  • Market Cap
  • EMBC 716.2M
  • SYRE 841.4M
  • IPO Year
  • EMBC N/A
  • SYRE 2016
  • Fundamental
  • Price
  • EMBC $11.97
  • SYRE $14.10
  • Analyst Decision
  • EMBC Hold
  • SYRE Buy
  • Analyst Count
  • EMBC 3
  • SYRE 8
  • Target Price
  • EMBC $17.67
  • SYRE $50.00
  • AVG Volume (30 Days)
  • EMBC 445.0K
  • SYRE 553.9K
  • Earning Date
  • EMBC 05-09-2025
  • SYRE 05-08-2025
  • Dividend Yield
  • EMBC 5.02%
  • SYRE N/A
  • EPS Growth
  • EMBC N/A
  • SYRE N/A
  • EPS
  • EMBC 0.89
  • SYRE N/A
  • Revenue
  • EMBC $1,079,500,000.00
  • SYRE N/A
  • Revenue This Year
  • EMBC N/A
  • SYRE N/A
  • Revenue Next Year
  • EMBC $0.99
  • SYRE N/A
  • P/E Ratio
  • EMBC $13.36
  • SYRE N/A
  • Revenue Growth
  • EMBC N/A
  • SYRE N/A
  • 52 Week Low
  • EMBC $10.12
  • SYRE $10.91
  • 52 Week High
  • EMBC $21.48
  • SYRE $40.49
  • Technical
  • Relative Strength Index (RSI)
  • EMBC 46.46
  • SYRE 48.32
  • Support Level
  • EMBC $12.08
  • SYRE $12.29
  • Resistance Level
  • EMBC $13.45
  • SYRE $15.77
  • Average True Range (ATR)
  • EMBC 0.59
  • SYRE 1.06
  • MACD
  • EMBC 0.13
  • SYRE 0.08
  • Stochastic Oscillator
  • EMBC 40.75
  • SYRE 52.08

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: